Frank P. Zemlan
Chief Executive Officer at Phase 2 Discovery, Inc.
Frank P. Zemlan active positions
| Companies | Position | Start | End |
|---|---|---|---|
Phase 2 Discovery, Inc.
 Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Chief Executive Officer | - | - |
Career history of Frank P. Zemlan
Former positions of Frank P. Zemlan
| Companies | Position | Start | End |
|---|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - | - |
| GSK PLC | Corporate Officer/Principal | - | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Training of Frank P. Zemlan
| Villanova University | Graduate Degree |
| University of Pennsylvania | Doctorate Degree |
Statistics
International
| United States | 6 |
| United Kingdom | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Executive Officer | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| GSK PLC | Health Technology |
| Private companies | 2 |
|---|---|
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Health Technology |
| Aventis, Inc. |
- Stock Market
- Insiders
- Frank P. Zemlan
- Experience
